AGTC to Participate at Upcoming Investor Conferences
BTIG Virtual Biotechnology Conference( August 9, 2021) Sue Washer, President & Chief Executive Officer, will participate in a fireside chat at 1:30 p.m. ETon Monday, August 9, 2021. Participants interested in listening to the live fireside chat may contact their BTIG conference representative.
Wedbush PacGrow Healthcare Virtual Conference( August 10-11, 2021) Ms. Washerwill participate in a panel discussion entitled: “Only Have Eyes For You - Ophthalmic Gene Therapy” at 8:00 a.m. ETon Wednesday, August 11, 2021. H.C. Wainwright Ophthalmology Virtual Conference( August 17, 2021)
A presentation by
Ms. Washerwill be available to view on-demand beginning Tuesday, August 17, 2021at 7:00 a.m. ETthrough the entirety of the conference.
Audio webcasts of the presentations at the Wedbush and H.C. Wainwright conferences can be accessed by visiting http://ir.agtc.com/events-and-presentations. Replays will be available on the Company's website following the events.
AGTC is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases. AGTC is a leader in designing and constructing all critical gene therapy elements and bringing them together to develop customized therapies that address real patient needs. AGTC’s most advanced clinical programs leverage its best-in-class technology platform to potentially improve vision for patients with an inherited retinal disease. AGTC has active clinical trials in X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM B3 and ACHM A3). Its preclinical programs build on the Company’s industry leading AAV manufacturing technology and scientific expertise. AGTC is advancing multiple important pipeline candidates to address substantial unmet clinical need in optogenetics, otology and CNS disorders. In recent years AGTC has entered into strategic partnerships with companies including Otonomy, Inc., a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, and
Chief Business Officer
T: (617) 413-2754
Source: Applied Genetic Technologies Corporation